CMS Off-Label Cancer Coverage Proposal Questioned By ASCO
Executive Summary
CMS' proposal to cover clinical trials evaluating four colorectal cancer drugs in off-label uses is not a wise use of taxpayer dollars, the American Society of Clinical Oncology suggests in comments on the draft policy
You may also be interested in...
Colorectal Cancer Policy Will Not Limit Current Off-Label Coverage, CMS Says
The Centers for Medicare & Medicaid Services' national coverage determination for four colorectal cancer therapies will not limit coverage of other off-label indications, the agency said
Colorectal Cancer Policy Will Not Limit Current Off-Label Coverage, CMS Says
The Centers for Medicare & Medicaid Services' national coverage determination for four colorectal cancer therapies will not limit coverage of other off-label indications, the agency said
CMS Developing Guidance On Coverage Decisions For Clinical Trials
The Centers for Medicare & Medicaid Services will produce a guidance document on Medicare coverage of products used in clinical trials or registries